Literature DB >> 8383439

Characterization of a common VIP-PACAP receptor in human small intestinal epithelium.

R Salomon1, A Couvineau, C Rouyer-Fessard, T Voisin, D Lavallée, A Blais, D Darmoul, M Laburthe.   

Abstract

Vasoactive intestinal peptide (VIP) receptors were characterized in epithelial plasma membranes from human small intestine. Native VIP inhibited the binding of 125I-labeled VIP to jejunal membranes, and Scatchard analysis of these data was consistent with the existence of one class of receptor with a dissociation constant of 42 pM and a maximal binding of 256 fmol/mg membrane protein. VIP stimulated adenylyl cyclase activity in human jejunal membranes in the 0.01 nM-1 microM range [half-maximal effective dose = 0.7 nM]. Coupling of VIP receptors with a Gs protein was further assessed by the ability of GTP (10(-8) to 10(-3) M) to inhibit 125I-VIP binding to membranes. 125I-VIP binding was seven to eight times higher in villus cells than in crypt cells. Finally, 125I-VIP binding was detectable throughout the small and large intestines with the highest binding in jejunum. Among the natural peptides structurally related to VIP, some inhibited 125I-VIP binding with the following order of potency: VIP = pituitary adenylate cyclase-activating peptide (PACAP)-27 = PACAP-38 > helodermin >> peptide histidine methionineamide = human growth hormone-releasing factor > secretin. The same order of potency of peptides for inhibiting 125I-VIP or 125I-labeled PACAP was observed, supporting that the two tracers bound to a common VIP-PACAP receptor site. This order of potency was also observed for the stimulation of adenylyl cyclase activity by these peptides. 125I-VIP was cross-linked to membranes using disuccinimidyl suberate. After sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis, one single band of 70,000 mol wt was observed.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8383439     DOI: 10.1152/ajpendo.1993.264.2.E294

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  13 in total

1.  Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells.

Authors:  Dalila Darmoul; Valérie Gratio; Hélène Devaud; Thérèse Lehy; Marc Laburthe
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

2.  Presence of endogenous PACAP-38 ameliorated intestinal cold preservation tissue injury.

Authors:  Andrea Ferencz; Gyorgy Weber; Zsuzsanna Helyes; Hitoshi Hashimoto; Akemichi Baba; Dora Reglodi
Journal:  J Mol Neurosci       Date:  2010-04-09       Impact factor: 3.444

Review 3.  Class II G protein-coupled receptors and their ligands in neuronal function and protection.

Authors:  Bronwen Martin; Rakel Lopez de Maturana; Randall Brenneman; Tom Walent; Mark P Mattson; Stuart Maudsley
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

4.  Kallikrein-related peptidase 14 acts on proteinase-activated receptor 2 to induce signaling pathway in colon cancer cells.

Authors:  Valérie Gratio; Céline Loriot; G Duke Virca; Katerina Oikonomopoulou; Francine Walker; Eleftherios P Diamandis; Morley D Hollenberg; Dalila Darmoul
Journal:  Am J Pathol       Date:  2011-09-09       Impact factor: 4.307

5.  The human vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor 1 (VPAC1) promoter: characterization and role in receptor expression during enterocytic differentiation of the colon cancer cell line Caco-2Cl.20.

Authors:  A Couvineau; J J Maoret; C Rouyer-Fessard; I Carrero; M Laburthe
Journal:  Biochem J       Date:  2000-05-01       Impact factor: 3.857

Review 6.  Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease.

Authors:  S G R Smalley; P A Barrow; N Foster
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

7.  Activation of cAMP-dependent C1- currents in guinea-pig paneth cells without relevant evidence for CFTR expression.

Authors:  T Tsumura; A Hazama; T Miyoshi; S Ueda; Y Okada
Journal:  J Physiol       Date:  1998-11-01       Impact factor: 5.182

8.  Pituitary adenylate cyclase-activating polypeptide, helospectin, and vasoactive intestinal polypeptide in human corpus cavernosum.

Authors:  P Hedlund; P Alm; P Ekström; J Fahrenkrug; J Hannibal; H Hedlund; B Larsson; K E Andersson
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

9.  Influence of PACAP on oxidative stress and tissue injury following small-bowel autotransplantation.

Authors:  Andrea Ferencz; Boglarka Racz; Andrea Tamas; Dora Reglodi; Andrea Lubics; Jozsef Nemeth; Klara Nedvig; Karoly Kalmar-Nagy; Ors Peter Horvath; Gyorgy Weber; Erzsebet Roth
Journal:  J Mol Neurosci       Date:  2008-07-24       Impact factor: 3.444

10.  Expression and localization of VPAC1, the major receptor of vasoactive intestinal peptide along the length of the intestine.

Authors:  Dulari Jayawardena; Grace Guzman; Ravinder K Gill; Waddah A Alrefai; Hayat Onyuksel; Pradeep K Dudeja
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-04-06       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.